Repurposing GLP-1 Receptor Agonists for Parkinson’s Disease: Current Evidence and Future Opportunities

Author(s):  
Daniella Balduino Victorino ◽  
Mariana Nejm ◽  
Marcia Guimarães-Marques ◽  
Fulvio Alexandre Scorza ◽  
Carla Alessandra Scorza
2021 ◽  
pp. 1-15
Author(s):  
Rafail Matzaras ◽  
Kuangyu Shi ◽  
Artemios Artemiadis ◽  
Panagiotis Zis ◽  
Georgios Hadjigeorgiou ◽  
...  

Background: REM-sleep behaviour disorder (RBD) is a parasomnia and a common comorbidity in Parkinson’s disease (PD). There is evidence that the presence of RBD is associated with more severe PD. The differences in the clinical manifestations and the natural history are likely to imply underlying differences in the pathophysiology among PD patients with and without RBD. The increasing number of neuroimaging studies support this notion. Objective: Our primary objective was to review the current evidence regarding the brain neuroimaging findings in PD patients with RBD (PDRBD). Methods: A systematic review of articles, published in PubMed between January 1, 2000 and September 23, 2020 was performed. We evaluate previous studies that assessed PD patients with RBD using various brain structural and functional magnetic resonance imaging (MRI) techniques and brain nuclear medicine imaging. Results: Twenty-nine studies, involving a total of 3,347 PD subjects among which 912 subjects with PDRBD, met the selection criteria and were included. The presence of RBD in PD patients is associated with structural and functional alterations in several brain regions, mainly in brainstem, limbic structures, frontotemporal cortex, and basal ganglia, raising the hypothesis of a PDRBD neuroimaging phenotype. Conclusion: The current review provides up-to-date knowledge in this field and summarizes the neurobiological/neuroimaging substrate of RBD in PD.


2019 ◽  
Vol 10 ◽  
Author(s):  
Meg E. Morris ◽  
Terry D. Ellis ◽  
Dana Jazayeri ◽  
Hazel Heng ◽  
Andrea Thomson ◽  
...  

2020 ◽  
Vol 10 (2) ◽  
pp. 523-542 ◽  
Author(s):  
Lingyu Zhang ◽  
Liping Zhang ◽  
Yanwei Li ◽  
Lin Li ◽  
Josefine Ulrikke Melchiorsen ◽  
...  

2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
Carina J. Bleickardt ◽  
Abigail L. LaShomb ◽  
Carrie E. Merkel ◽  
Robert A. Hodgson

Parkinson's disease (PD) is characterized by loss of dopaminergic neurons in the substantia nigra. Current treatments for PD focus on dopaminergic therapies, including L-dopa and dopamine receptor agonists. However, these treatments induce neuropsychiatric side effects. Psychosis, characterized by delusions and hallucinations, is one of the most serious such side effects. Adenosine receptor antagonism is a nondopaminergic treatment for PD with clinical and preclinical efficacy. The present studies assessed antagonists SCH 412348 and istradefylline in rodent prepulse inhibition (PPI), a model of psychosis. Dopamine receptor agonists pramipexole (0.3–3 mg/kg), pergolide (0.3–3 mg/kg), and apomorphine (0.3–3 mg/kg) significantly disrupted PPI; ropinirole (1–30 mg/kg) had no effect; L-dopa (100–300 mg/kg) disrupted rat but not mouse PPI. SCH 412348 (0.3–3 mg/kg) did not disrupt rodent PPI; istradefylline (0.1–1 mg/kg) marginally disrupted mouse but not rat PPI. These results suggest that antagonists, unlike dopamine agonists, have an improved neuropsychiatric side effect profile.


2016 ◽  
Vol 46 (8) ◽  
pp. 971-977
Author(s):  
E. A. Katunina ◽  
N. V. Titova ◽  
Yu. N. Bezdol’nyi ◽  
R. K. Shikkerimov ◽  
M. G. Gasanov ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document